Myelodysplastic syndromes: the role of the immune system in pathogenesis

References

• Marisavljevic D, Kraguljac N, Rolovic Z. Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 2006;23:385–392.
   PubMed Web of Science ®Google Scholar
• Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes–clinical and cytogenetic features. Eur J Haematol 1995;55:42–48.
   PubMed Web of Science ®Google Scholar
• Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25:1075–1083.
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998;102:1314–1322.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002;119:97–105.
   PubMed Web of Science ®Google Scholar
• Miller JS. Biology of natural killer cells in cancer and infection. Cancer Invest 2002;20:405–419.
   PubMed Web of Science ®Google Scholar
• Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003;90:127–156.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Bourgeois E, Lobe I, . Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006;20:463–470.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Bai F, Painter JS, . Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109:4816–4824.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Baumann BC, Simonsson M, . Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34(þ) blasts in myelodysplastic syndrome. Leukemia 2010;24: 1607–1616.
   PubMed Web of Science ®Google Scholar
• Smith MA, Smith JG. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991;15: 597–601.
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699–705.
   PubMed Web of Science ®Google Scholar
• Jonasova A, Neuwirtova R, Cermak J, . Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100:304–309.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Painter JS, Rollison DE, . Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 2007;21:659–667.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Ingram W, Hayden J, . CD4þCD25high Foxp3þ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007;110:847–850.
   PubMed Web of Science ®Google Scholar
• Hamdi W, Ogawara H, Handa H, Tsukamoto N, Nojima Y, Murakami H. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome. Eur J Haematol 2009;82:201–207.
   PubMed Web of Science ®Google Scholar
• Kotsianidis I, Bouchliou I, Nakou E, . Kinetics, function and bone marrow trafficking of CD4þCD25þFOXP3þ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009;23:510–518.
   PubMed Web of Science ®Google Scholar
• Alfinito F, Sica M, Luciano L, . Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 2010;148:90–98.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273–2284.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162–174.
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53–65.
   PubMed Web of Science ®Google Scholar
• Ugel S, Delpozzo F, Desantis G, . Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9:470–481.
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439–5449.
   PubMed Web of Science ®Google Scholar
• McCormack SE, Warlick ED. Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine. Onco Targets Ther 2010;3:157–165.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, . Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895–3903.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–1465.
   PubMed Web of Science ®Google Scholar
• Tang KF, He CX, Zeng GL, . Induction of MHC class I-related chain B (MICB) by 5-aza-2’-deoxycytidine. Biochem Biophys Res Commun 2008;370:578–583.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kuick R, Hanash S, Richardson B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol 2009;130:213–224.
   Google Scholar
• Santourlidis S, Trompeter HI, Weinhold S, . Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002;169: 4253–4261.
   PubMed Web of Science ®Google Scholar
• Gao XN, Lin J, Wang LL, Yu L. Demethylating treatment suppresses natural killer cell cytolytic activity. Mol Immunol 2009; 46:2064–2070.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, . Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192–203.
   PubMed Web of Science ®Google Scholar
• Chan AC, Neeson P, Leeansyah E, . Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010;24:592–600.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Giagounidis AAN, Simcock M, . Immuno-suppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011;29:303–309.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Wu CO, Greenberg P, . Factors affecting response and survival in patients with myelodysplasia with immunosuppressive therapy. J Clin Oncol 2008;26:2505–2511.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011;305:814–819.
   PubMed Web of Science ®Google Scholar